Article
In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease.
Journal of clinical pharmacology - 1 Nov 2005
Ohnishi Akihiro, Murakami Shigeto, Akizuki Setsuko, Mochizuki Junko, Echizen Hirotoshi, Takagi Ichiro
Abstract excerpt
To study whether chronic liver disease (CLD) and genetic polymorphism affect the hepatic activity of cytochrome P450 (CYP) isoforms, we compared in vivo CYP2C19 and CYP3A activities using 3-hour omeprazole hydroxylation index (plasma concentration ratio of omeprazole to its 5-hydroxylated metabolite; a higher index indicates lower CYP2C19 activity) and partial formation clearance of cortisol to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
